SN
Shai Novik M.B.A.
Executive Chairman
Chairman
born 1966comp · $528,000
LOADING SNAPSHOT
Fetching the books…
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.
For commercial pharma: watch patent cliffs and competition. For pre-revenue biotech: cash runway and trial readouts.
Mixed signals — interesting but with caveats. Worth a deeper look before committing capital.
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin | Source |
|---|---|---|---|---|---|---|
| 2020-12-31 | — | — | $-9.79M | $-11.82M | — | 20-F ↗ |
| 2021-12-31 | — | — | $-19.29M | $-14.47M | — | 20-F ↗ |
| 2022-12-31 | — | — | $-25.80M | $-31.06M | — | 20-F ↗ |
| 2023-12-31 | — | — | $-29.39M | $-29.07M | — | 20-F ↗ |
| 2024-12-31 | — | — | $-15.89M | $-15.01M | — | 20-F ↗ |
| 2025-12-31 | — | — | $-15.03M | $1.24B | — | 20-F ↗ |
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.